The Therapeutic Goods Administration has issued three infringement notices totalling $11,880 to a NSW nurse over the alleged unlawful importation of unapproved cosmetic injectables.
Published on 6 July 2026, the TGA said the nurse, who is registered with Ahpra, allegedly imported unapproved vials of botulinum toxin and pre-filled syringes containing lidocaine. The infringement notices were issued in May 2026.
The regulator said the products were not listed in the Australian Register of Therapeutic Goods (ARTG), meaning they had not been assessed by the TGA for quality, safety or efficacy.
‘Therapeutic goods that are not listed in the Australian Register of Therapeutic Goods, also known as unapproved therapeutic goods, have not been assessed by the TGA for quality, safety and efficacy and therefore may pose a health risk,’ the regulator said.
The latest action adds to a growing pattern of enforcement across cosmetic medicine, wellness and online therapeutic goods supply.
As previously reported by Aesthetic Medical Practitioner, the TGA has been steadily increasing scrutiny of unlawful importation, supply and advertising activity across the sector. In March, the regulator issued infringement notices to three health practitioners for the alleged unlawful importation of unapproved therapeutic goods, including products used in cosmetic and IV-based treatments.
In May, more than 900,000 unlawfully imported therapeutic goods were seized in Australia as part of INTERPOL’s Operation Pangea XVIII, with counterfeit botulinum toxin and semaglutide products among the goods reported or seized during the global crackdown.
More recently, the TGA expanded its compliance focus to include unapproved peptide products, citing increased detection of unlawful importation, advertising and online supply, as well as emerging concerns around safety, sterility, dosing uncertainty and unknown product composition.
The regulator has also released new guidance on advertising restrictions for prescription medicines, including cosmetic injectables, peptides and weight-loss injections, making clear that businesses cannot use indirect language, substitute terms or public-facing booking systems to promote access to prescription medicines where this would breach the Therapeutic Goods Act 1989.
The TGA said it works with law enforcement agencies, other health regulators and state and territory authorities to address unlawful activity in the wellness and beauty industries.
‘In recognition of their potential harm and increased use, the TGA is targeting unapproved therapeutic goods used in cosmetic procedures as part of its Compliance Principles 2026 and 2027,’ the regulator said.
The latest enforcement action comes as aesthetic clinics continue to navigate tightening expectations around sourcing, prescribing, storage, advertising and public communication of prescription-only products.
The TGA has stressed individuals, health practitioners and businesses must understand their legal obligations under the Act before importing or advertising therapeutic goods. Consequences for non-compliance may include infringement notices, direction or prevention notices, or civil or criminal proceedings.
